What does Autolus Therapeutics plc do?

Autolus Therapeutics plc is a public company in the Biological Products, (No Diagnostic Substances) industry, incorporated in X0. It is registered with the SEC under CIK 0001730463 and trades on NASDAQ under the ticker AUTL.

What is Autolus Therapeutics plc's annual revenue?

Autolus Therapeutics plc reported $10.12M in revenue for fiscal year 2024, according to its 10-K filing with the SEC.

Is Autolus Therapeutics plc profitable?

Autolus Therapeutics plc reported a net loss of $287.53M in FY2025. This figure is sourced from its SEC EDGAR 10-K annual report.

How many SEC filings has Autolus Therapeutics plc made?

Autolus Therapeutics plc has filed 296 documents with the SEC since 2018. These include annual reports (10-K), quarterly reports (10-Q), current event notices (8-K), and insider transaction disclosures (Form 4).

Autolus Therapeutics plc

AUTL NASDAQ CIK: 0001730463 Biological Products, (No Diagnostic Substances) Inc. in X0

View on SEC.gov →

Overview All Filings Annual Quarterly Insiders

Recent Filings

All 296 filings →

Form	Description	Date
10-K	10-K	Mar 27, 2026
8-K	8-K	Mar 27, 2026
3	—	Mar 23, 2026
3	—	Mar 18, 2026
3	—	Mar 18, 2026
3	—	Mar 18, 2026
3	—	Mar 18, 2026
3	—	Mar 18, 2026
3	—	Mar 18, 2026
3	—	Mar 18, 2026

Insider Transactions

View all →

No insider transactions loaded yet.

About This Profile

This page aggregates all publicly available SEC EDGAR data for Autolus Therapeutics plc. Financial figures are sourced from XBRL-tagged 10-K annual reports. Insider transactions are sourced from Form 4 filings required within two business days of a transaction.

Key Financials

Revenue: $10.12M (FY2024)
Net Income: ($287.53M) (FY2025)
Total Assets: $589.07M (FY2025)
Operating Income: ($270.54M)

Full financials →

Details

CIK: 0001730463
Ticker: AUTL
Exchange: NASDAQ
Incorporated: X0
First Filing: 2018
Total Filings: 296

Biological Products, (No Diagnostic Substances) rankings →